Sight Sciences' TearCare Surpasses Restasis Dry Eye Treatment, Trial Data shows
Portfolio Pulse from Vandana Singh
Sight Sciences Inc (NASDAQ:SGHT) has released six-month trial data showing that its TearCare Technology, used in interventional eyelid procedures for dry eye disease, has surpassed Restasis in effectiveness. The trial met its primary endpoint, with statistically significant improvements compared to Restasis eye drops. The next phase of the study will see subjects in the Restasis cohort switch to TearCare, with final results expected by 2025. SGHT shares are up 0.91% at $7.78.
July 20, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sight Sciences' TearCare Technology has shown superior results to Restasis in treating dry eye disease, potentially boosting the company's market position. SGHT shares are up 0.91%.
The positive trial results for Sight Sciences' TearCare Technology indicate a potential increase in market share as it proves to be more effective than Restasis. This positive news is likely to increase investor confidence, reflected in the 0.91% increase in SGHT shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100